MVision AI Oy

Based in Finland, MVision AI Oy develops innovative AI-powered solutions for radiation therapy, enhancing treatment planning and patient care through advanced technologies. MVision AI Oy specializes in creating advanced solutions for radiation therapy, with a focus on improving cancer treatment through AI technology. The company was founded in 2017 in Helsinki, Finland, by Aleksi Nurmi, Jarkko Niemela, Mahmudul Hasan, and Saad Akram. The CEO, Jarkko Niemela, leads the firm, which has engaged in a total of 3 deals.

Most recently, in March 2023, MVision AI Oy raised EUR 5. 4 million in funding from investors J12 Ventures and Voima Ventures. This round marked the total amount raised by the company at EUR 5. 4 million.

MVision AI specializes in advanced AI-powered solutions for radiation therapy, primarily through its flagship products, Dose+ and the Guideline-Based Segmentation (GBS™) suite. Dose+ enhances treatment planning for radiation therapy professionals by providing patient-specific dose predictions, facilitating efficient plan optimization. Initially validated for prostate and pelvic lymph node cases, it leverages machine learning techniques to minimize manual interactions during inverse planning without sacrificing plan quality. The GBS™ suite includes three key tools: Contour+, an AI-powered auto-contouring software; Verify, for assessing contour accuracy; and Guide, a training environment aimed at improving practitioners' skills.

This comprehensive offering serves radiation oncology professionals across 20 countries, addressing the needs of over 190,000 cancer patients annually, and integrates seamlessly with all DICOM-compliant treatment planning systems. In the most recent fiscal year of 2023, MVision AI reported a revenue of EUR 2,815,831. 40 and an EBITDA of EUR -1,752,814. 20.

The company operates by engaging directly with healthcare providers, including hospitals, clinics, and radiation therapy centers, through subscriptions or licensing agreements for its software solutions. In March 2023, MVision AI Oy secured EUR 5. 4 million in funding to develop new products aimed at facilitating cancer treatment and to establish a globally scalable cloud-based platform for cancer care. The company plans to enhance its product offerings while targeting expansion into new markets globally, focusing particularly on regions that can benefit from advanced radiation therapy solutions.